Skip to content

Author

Kaviarasan Lakshmanan

We have 3 of 24 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Computational Identification of Shikimic Acid Derivatives as Potential SARS-CoV-2 Inhibitors: An In Silico Approach.

The docking, ADMET, and MD simulation studies indicate that the designed shikimic acid derivatives have good binding affinity and drug-like properties, and are stable in the active site of the SARS-CoV-2 main protease.

Hardha Balachandran, Kaviarasan Lakshmanan, Dipen Purohit et al. · 0 citations
Review Aug 2026

Multi-target Drug Discovery for Cancer Therapy: A Contemporary Review.

MKIs and bispecific antibodies represent transformative modalities in modern oncology, supported by robust clinical evidence and extensive patent activity.

Thirumalaikumaran Rathinam, S. Reddy, Yella Sirisha et al. · 0 citations
Aug 2026

Design and Evaluation of Naphthoxy and Phenoxy amide as Potential PARP 1 inhibitors: Molecular Docking and In Vitro Analysis.

Overall, compound B2 emerged as a promising PARP1 inhibitor with strong binding affinity, structural stability, and significant in vitro anticancer activity, warranting further optimization and preclinical investigation.

Hardha Balachandran, Subhajit Majumder, Gowramma Byran et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.